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Osteoarthritis (OA) is the most common type of arthritis and a major cause of chronic musculoskeletal
pain and functional disability. While both pharmacologic and non-pharmacologic modalities are rec-
ommended in the management of OA, when patients with hip or knee OA do not obtain adequate pain
relief and/or functional improvement, joint replacement surgery or other surgical interventions should
be considered. Total joint arthroplasties are reliable and cost-effective treatments for patients with
signiﬁcant OA of the hip and knee. Evidence from cohort and observational studies has conﬁrmed
substantial improvements in pain relief with cumulative revision rates at 10 years following total hip
(THA) and total knee arthroplasties (TKA) at 7% and 10%, respectively. Joint replacements have been used
in most every synovial joint, although results for joints other than hip and knee replacement have not
been as successful. The evolution of new device designs and surgical techniques highlights the need to
better understand the risk to beneﬁt ratio for different joint replacements and to identify the appropriate
methodology for evaluating the efﬁcacy and optimal outcomes of these new devices, designed to treat
OA joints.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
1n 1999, the Food and Drug Administration (FDA) drafted
a guidance document for industry on clinical development
programs for drugs, devices, and biological products intended for
the treatment of Osteoarthritis (OA)1. Since thenmuch progress has
been made in the development of devices and drugs for the
treatment of OA leading the FDA to request additional information
to assist in their ongoing work to ﬁnalize the draft guidance.
Beginning in 2007, the Osteoarthritis Research Society Interna-
tional (OARSI) convened a number of working groups represented
by leading researchers, academicians and clinicians to lead a critical: V.M. Goldberg, University
aedics, 11100 Euclid Avenue,
V.M. Goldberg).
s Research Society International. Pappraisal of the scientiﬁc advances made over the past decade
related to OA. The Working Group on Devices considered a number
of key issues, including the appropriate study design and outcome
measurements that should be considered in clinical development
programs for new devices designed to treat OA joints.
The Medical Device Amendments of 1976 deﬁned devices as an
entity intended for diagnosis, cure mitigation or prevention of
a disease or condition or an entity intended to affect the function or
structure of the body that does not achieve its primary intended use
through chemical action or metabolism.Overview
Total hip (THA) and total knee arthroplasty (TKA) have both
shown effectiveness in relieving arthritis associated pain,
improving physical function, and enhancing health-related quality
of life2,3. Favorable outcomes following THA and TKA are wellublished by Elsevier Ltd. All rights reserved.
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of the surgical and technical aspects of arthroplasty, but also on
patient centered outcomes, including patient satisfaction4.
Evidence from cohort and observational studies has conﬁrmed
substantial improvements and durability of the devices with
cumulative revision rates at 10 years following THA and TKA at 7%
and 10%, respectively5. Joint replacements have been used in almost
every synovial joint; however, results for other joints have not been
as successful as those observed after hip and knee replacement.
Newer device designs and surgical techniques are rapidly
evolving. For example, spinal OA presents a signiﬁcant healthcare
problem in the USA resulting in severe disability and enormous
societal costs. New products for spinal pathologies are being
developed, including cervical and lumbar disc replacement, lumbar
dynamic internal ﬁxation stabilization, facet replacement, and
interspinous distraction devices. To date, these new products have
met with variable outcomes in clinical use6,7.
Hyaluronans (HA) represent another area of research. While HA
have been used intra-articularly as an approach to the treatment of
the pain associated with knee OA, recent preclinical studies sug-
gested that HAmay also have a diseasemodifying effect on articular
cartilage8. However, no clinical studies have conﬁrmed this
potential mechanism of action9e11.
Implantable biological devices, such as cell-based treatments for
repair of articular cartilage, have also recently been introducedwith
variable results12.
FDA: regulatory pathway for device approval
Many of the devices recently introduced to the marketplace fol-
lowed the FDA 510(k) guidance. A 510(k) is a premarket submission
made to the FDA demonstrating that the device to be marketed is as
safe and effective (i.e., substantially equivalent) and is similar to
a currently marketed device (a predicate device). Much of the
necessary information required for approval of the proposed device
is based on the previous assessment of the predicate device.
Companies must compare their proposed device to one or more
similar marketed devices and provide support of their “substantial
equivalency” claim. Once a new device is determined by the FDA to
be substantially equivalent, it can be marketed in the USA. The
parameters bywhich a device is considered to be equivalent include:
 Having the same intended use as the predicate device; and
Having the same technological characteristics as the predicate;
or
 Having the same intended use as the predicate; and
Having different technological characteristics and the infor-
mation submitted to the FDA:
e Does not raise new questions of safety and effectiveness;
and
e Demonstrates that the device is at least as safe and effect as
the currently marketed device.
If a device is not considered substantially equivalent, a company
may be required to submit a premarket approval application (PMA).
The PMA requires far more scientiﬁc and regulatory documentation
to the FDA demonstrating the safety and effectiveness of the device
than is necessary for a 510(k). Occasionally, the FDA will require
a short-term clinical trial as part of a 510(k) clearance; however,
randomized controlled trials, registries, and retrospective reviews
performed to further assess the efﬁcacy of the device are typically
required post approval13e15.
In 1999, Dr Henrik Malchau presented a conceptual approach to
device approval that spans both the 510(k) and PMA process,
without the intention of ﬁtting the framework into the currentregulatory process. This approach included a phased innovation
process of preclinical study followed by rigorous quantitative
metrics to assess the true effectiveness of the device16,17. Preclinical
metrics would be established through existing standards produced
by the American Society for Testing and Materials (ASTM) or the
International Organization for Standardization (ISO), as well as
other guidelines developed speciﬁcally for each device. Examples of
rigorous clinical metrics that he suggested would include validated
physician and patient directed clinical assessment tools and
quantitative measures to assess the functional abilities of the
patient. Thesemight include kinematic studies, unique quantitative
measures such as Radiostereometric Analysis (RSA) methodologies,
or simple tools such as muscle testing and the sit-to-stand and 6-
min walk tests.
Regardless of the care with which safety and effectiveness of
a new device are determined through preclinical studies or pre-
approval clinical trials, the ultimate assessment of its performance
emerges through post-market surveillance. The Swedish Hip and
Knee Registries, for example, have provided data for the successful
assessment of the survival of devices used by a broad spectrum of
surgeons in sufﬁcient numbers of patients leading to more cost-
effective approaches for the use of devices18e20. A limitation of
many registries, however, is that they use revision surgery as the
primary and often only outcome measure, with little or no infor-
mation on patient-reported outcomes. Nonetheless, the use of
registries provides a valuable tool in establishing performance and
could be adapted to the study of unique implantable biological
devices and products that combine biologics, drugs, and devices.
In anticipation of the increased demand for total joint arthro-
plasties and the continued advancements in the development of
other devices, biologics, and new surgical techniques for the
treatment of OA, it is important to consider how the efﬁcacy,
beneﬁt to risk ratio, and clinical outcomes of these new products
will be assessed.Measuring the efﬁcacy of devices
Devices, especially orthopaedic devices, do not ﬁt into the same
deﬁnition of efﬁcacy deﬁned by the FDA for pharmacological
treatments. The time course for showing efﬁcacy in a device such as
a total joint replacement is usually much longer than pharmaco-
logic treatments, since devices are intended to demonstrate pain
relief and return of function over a period of years. Efﬁcacy early in
the time course may reﬂect the variables associated with the
surgical procedure and not the performance of the device itself. The
compromise for assessing the efﬁcacy of joint replacement has
been to select a suitable time frame combined with acceptable
outcomes that reﬂect efﬁcacy. For joint arthroplasty, for example,
orthopaedic surgeons and the editorial boards of respected peer-
reviewed orthopaedic journals have accepted 2 years as the
minimum acceptable time period for assessing efﬁcacy. Acceptable
measures of efﬁcacy are less agreed upon, though most joint
arthroplasty surgeons rely on hip or knee scores that encompass
both pain and function. However, speciﬁc instruments to measure
efﬁcacy of devices that have been validated and reﬂect outcomes
include the Western Ontario McMaster University Osteoarthritis
Index (WOMAC) , the Knee Society Clinical Rating System and
the Oxford-1 Item Questionnaire for the knee. The hip outcome
measures that are validated include the Harris Hip Score and the
Hospital for Special Surgery Hip Rating. These latter scoring
systems, however, do not take into consideration changes in the
patient’s medical condition and age so that a Short-Form Health
Survey (SF-36) is useful to assess the health-related quality of life
aspects of outcome21.
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manufacturers and should remain. However, the effectiveness of
the implant should be differentiated from that of the surgical
procedure. Additional research should focus on what speciﬁc
endpoints can be assessed to determine failure modes. Currently
a device with a relatively low failure rate, as identiﬁed by data
collected from a large number of surgeons/surgical procedures, is
considered efﬁcacious. It is unlikely, however, that a common time
point such as 2 years is appropriate for all devices used in the
treatment of OA. Certain failure modes for joint replacements, such
as osteolysis, are know to emerge only after many years of service,
while new devices that incorporate biologics or drugs may
demonstrate effectiveness over time courses much shorter than 2
years.
HA-based viscosupplements are currently indicated for the
treatment of pain related to knee OA that is unresponsive to simple
analgesics. These products require clinical safety and efﬁcacy data
as part of their PMA application to obtain FDA approval. Because
they are intended to treat pain, viscosupplements have effective-
ness endpoints that are similar to that expected for pharmacolog-
ical OA pain treatments. However, viscosupplements and biologic
devices differ from some of the other pharmacological therapies in
that the treatments are conﬁned to the joint in question and the
expected effect is sustained pain relief for 3 months or longer in the
treated joint.
For purposes of drug approval, the current FDA draft guidance
for HA viscosupplements should allow for measurements speciﬁc
to the treated joint. For example, in patients with OA in more than
one knee joint or one hip joint, the patient-reported outcome of
pain, function, and stiffness should be for the treated joint alone.
Several approaches could be implemented to address this issue
during clinical development programs for the treatment of OA pain
with a medical device, including enrolling patients with a single
joint disease (which may be daunting since bilateral disease is far
more common), treating all affected joints, analyzing patients
separately based on whether all symptomatic OA was treated or
not, and using subscales that may be more speciﬁc for the treated
joint, such as the WOMAC A-1 pain on walking22.
Determining the relative risk to beneﬁt of new devices
It is important for devicemanufacturers towork closely with the
FDA and the clinical community to adopt special controls aimed at
minimizing risk while providing an avenue for maximizing beneﬁt.
Establishing with the FDAwhat additional data (preclinical, clinical,
and post-market) are needed to show substantial equivalence or
claimed improvements with both the surgery and the device and
gaining consensus on the appropriate control groups are important
steps. Minimal standards should be obtained from the existing
ASTM and ISO standards. While a claimed improvement by a new
device over an existing device (e.g., improved wear performance,
kinematics, or ﬁxation) could be tested with existing standards,
situations will arise for which an appropriate, validated test is
unavailable. Therefore, tests that have been developed within the
scientiﬁc community and published in the peer-reviewed literature
could be considered. Changing over to a relative risk vs beneﬁt
would enhance the present 510K pathway that in many circum-
stances is used by device manufacturers to circumvent the more
difﬁcult Class III pathway.
Clearly, risk is associated with every device and every proce-
dure. For a new Class II device, the risks should be minimized by
comparing with a predicate device plus utilizing additional tests to
demonstrate the safety and efﬁcacy of any new claims. However,
risk is not constant for a given device for every patient. For example,
the risk of loosening and wear is higher with heavier and moreactive patients21. Yet it is unrealistic or even impossible to design
every device to function indeﬁnitely without problems in the
“worst case scenario”. In this circumstance, the patientephysician
relationship is central in importance.
HA-based supplements, since they are indicated for pain relief,
require a patient-reported outcome. To adequately assess the
safety and effectiveness of HA-based supplements, the patient and
other reporters need to be blinded to treatment selection. An
appropriate control would need to incorporate an intra-articular
or sham injection and be perceived by the patient as being the
same as an intra-articular injection of the study device. Visco-
supplement trials have included the following treatments and
controls in an effort to blind the patients to treatment: intra-
articular injections of phosphate buffered saline, an already
approved viscosupplement, or glucocorticoid, or a sham injection.
Depending on the trial design (e.g., non-inferiority to an active
available pain relief product or superiority to a non-active treat-
ment or an active treatment) any of these control options are
acceptable. However, improvement compared to some other
therapy requires not only statistical superiority (or non-inferiority
as the case may be) but also clinically meaningful improvements
in the outcome. Since clinical relevance is open to debate, but
must be established prior to initiating the regulatory pathway for
new products, early consultation and regular communicationwith
the appropriate review division at the FDA is desirable. If non-
inferiority to an active comparator is to be pursued, then estab-
lishing an acceptable margin of non-inferiority is critical: the
smaller the margin, the larger the trial. The approach is applicable
to other injectables and biological device, e.g., BMP-2.
Optimal outcome parameters for evaluation
Pain relief, restoration of function (range of motion (ROM),
6 min walk), other functional observed and measured performance
outcomes as previously discussed, assessment of radiographs and/
or other images, complications and complication rates, revision and
revision rates are all validated and optimal approaches to deﬁning
outcomes22,23. Each of these measures is important and valuable to
provide a comprehensive quantitative assessment of the device
outcome from the physicians’ perspective. However, patient-
reported self-assessment outcomes are critical in that they give
a speciﬁc measure of performance in relation to patient expecta-
tions, independent of evaluation by medical staff. Independent
living, work status, and return to recreational sports and related
activities may also be indicators for restoration of function. A
number of instruments have been validated to deﬁne outcome
measures from either physician-derived or patient-reported
measures. These include the Harris Hip Score, the new Knee Society
Scoring System, and the WOMAC. The quality of life measures that
are important in determining the effectiveness of medical treat-
ments, including biological devices, include the SF-36 (medical
outcome study short form) and the quality of life evaluation and
health assessment questionnaire (HAQ).
Optimal global assessment tools for evaluating the outcome of
HA-based viscosupplements on pain and function in a single target
joint include but are not limited to the visual analog scale (VAS) for
pain, the WOMAC scale, and patient directed study instruments
such as the SF-36 outcome form, the Lequesne Functional Index,
and the OARSI-Outcome measures in rheumatology clinical trials
(OMERACT) responder rate24,25. Until now the most prevalent
primary endpoint has been a VAS pain measurement in the treated
joint and patient-reported outcome tools in the WOMAC and PTTA
instruments. Outcome measures of biological devices may require
speciﬁc structural outcome measures such as magnetic resonance
imaging (MRI) biomarkers for cartilage quality as deﬁned in the
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incorporate validated and veriﬁable outcome tools and can be used
to measure a beneﬁt of biological devices for the treatment of OA.
Are outcome parameters substantially different with respect
to different joints?
The intended goals for surgical treatment of OA across all joints
include pain relief, restoration of function, independent living and
return to productive employment, and a low re-operation rate
within 10 years of the incident procedure. However, speciﬁc
parameters and criteria exist for success directly related to each
joint. These parameters are best reﬂected in the numerous vali-
dated assessment tools both from the physician and the patient
point of view that have been developed by the specialty societies
addressing each anatomical area. For example, the glenohumeral
joint is addressed by a number of speciﬁc shoulder assessment
tools including the Western Ontario OA Scale for the shoulder. The
American Academy of Orthopaedic Surgeons (AAOS) subscale for
the ankle is another example of a joint speciﬁc assessment tool26.
The general goals for treatment with HA-based viscosupple-
ments are also the same across all joints: pain relief and functional
improvement. However, as with devices, speciﬁc measurement
tools have been designed for load bearing vs non-load bearing
joints. These tools as described above should be considered on
a case-by-case basis for speciﬁc joints.
Assessment of short-term vs long-term beneﬁts
Orthopaedic devices used for joint replacement have a goal of
long-term success, that is the permanent replacement of the joint
bearing surfaces. Short-term beneﬁts are important in regard to
complications that accompany the surgical implantation; from
a regulatory standpoint, these include complicationsdirectly related
to surgical instrumentation or to the device itself. However, the
ultimate goal of long-term beneﬁt must be considered. In this
respect, orthopaedic devices differ frommost othermedical devices.
A 2-year time period with suitable evaluation methods will deﬁne
problems such as premature loosening, instability, or inadequate
motion. Additional evaluation might be required for Class II devices
with special claims.
Biological devices are similar to HA-based viscosupplements in
that short-term beneﬁts are critical. These products should be
studied over a 3e6 month period, and repeat injections should be
performed to assess the safety of repeated injections. Post-
marketing surveillance is critical, as these products have not shown
pain relief in all patients. A speciﬁc responder analysis should be
carefully monitored to determine the outcomes of success or
failure. Their measured beneﬁt should not only be in terms of
statistical improvement to a comparator but should also be clini-
cally relevant.
Assessment of complications and other adverse events and
their prevention
The complications of orthopaedic devices are well documented
and numerous studies have provided data on their incidence,
causes and preventive measures27,28. The prevention of device-
related complications begins with rigorous preclinical testing. The
importance of well-designed clinical programs cannot be over
emphasized. There are, however, complications that are associated
not with the device, but introduced by inadequate instrumentation,
by surgical factors such as incorrect ligament balancing, poor
cement technique, mal-rotations of components, or even by the
patient themselves. Complications must be clearly attributed tothe device as opposed to related to surgical or patient issues. If
possible the preclinical testing should include studies which expose
the sensitivity of devices to such occurrences. Speciﬁc device
adverse events would include premature wear, breakage and early
loosening.
HA-based supplements also have a history of adverse events.
The adverse events are typically divided into those related to the
injection procedure itself and those related to the HA material
injected into the intra-articular joint space. The same is true with
biological devices. Although signiﬁcant clinical data exist on the
knee, less clinical data are available for other joints and new safety
issues or signals may exist for these joints. Typical complications
occurring in the knee include injection site pain, erythema, effu-
sion, stiffness, or potential allergic reaction to the material.
However, the severity of these adverse events is usually mild to
moderate, and the reported problems resolve spontaneously. No
long-term complications have been reported. Continued post-
market surveillance with standardized criteria should continue.
Clinical indications
The clinical indications for joint replacement are well docu-
mented and include limitation of function of any given joint either
due to pain or malfunction to justify the risk of surgical interven-
tion and introduction of a foreign body with the intent of relief of
pain and restoration of function of the joint29,30.
The clinical indications for the use of HA-based viscosupple-
ments include treatment of patients with pain from OA of the knee
who have failed to respond to conservative non-pharmacological
therapy and simple analgesics31. Presently no viscosupplements are
approved for non-knee joint involvement in the United States,
though a number of clinical trials are being conductedwith the goal
of extending these treatment modalities to other joints. No well-
documented indications exist for biological treatments (devices),
used for cartilage repair and considerable work must be completed
by the FDA in developing guidance documents for the regulation of
these products. Collaboration with the scientiﬁc community is
required.
Balancing the cost associated with devices against
conservative therapy
This is a timely, though difﬁcult area to address. Essential to
understanding this relationship should be a quality of life estimate
so that both economic costs and patient derived satisfaction are
considered. There is a strong subjective element, which relates to
the patientephysician relationship. A central question is whether
a patient is prepared to continue with conservative treatment for
an extended time period, functioning sub optimally and experi-
encing pain, because they believe that a total joint or a biological
device has a limited lifetime with a measurable risk for an early
revision; or does the patient prefer early treatment with restoration
of function and relief of pain, but with the risk of a failure of the
device requiring revision in the future. No well-validated studies
address the issue of deﬁning the true risks and beneﬁts of these
procedures in the long term and how they affect cost. Careful
consideration of the issues of quality of life and its concomitant
economic costs must be considered for any evidence-based deci-
sion making process.
HA-based viscosupplements and biological intra-articular
treatment may be indicated for pain relief in patients where simple
analgesics have failed. Data indicate that HA-based viscosupple-
ments may provide long-term pain relief with only one treatment
and could be cost effective. However, further studies should be
done speciﬁcally to address the issue of cost-effectiveness of intra-
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tive therapy.
Moving forward
To further our understanding of orthopaedic devices, their
safety and efﬁcacy, relative beneﬁts and risk, and long-term
outcomes, the following recommendations have emerged from
literature reviews, clinical experience, and group consensus:
 Meta-analyses of clinical results with current technologies
should be undertaken with emphasis on demonstrating safety
and efﬁcacy by identifying types of complications, their preva-
lence, their timing, and their relationship (if any) to the device.
Meta-analysis should also be undertaken for revisions. Current
national and Medicare registries do not contain enough infor-
mation to make these recommended efﬁcacy determinations.
 A meta-analysis of current outcome measures (patient- and
surgeon-derived questionnaires, objective measures like the
6 minwalk, etc.) should be performed and a consensus reached
on the most appropriate outcome measures to be utilized.
Multi-center prospective studies using non-developer partici-
pants are needed. This effort might be of importance in revising
existing national registries outside the USA and in establishing
a US registry as a means of including outcome measures
beyond revision surgery as the endpoint of a joint replacement.
 Research is necessary to establish the efﬁcacy of existing and
proposed standards within the context of regulatory science.
Existing standards should be challenged on the basis of
objective scientiﬁc and cost data to establish whether the
standards have demonstrated device performance in a clini-
cally meaningful way. Efforts by FDA to accept voluntary
standards as part of the special controls used in the regulatory
process should be encouraged through collaborative efforts
among FDA, device manufacturers, and the scientiﬁc and
clinical communities.
 A national device registry should be established with well-
deﬁned goals. This registry would as example characterize
practice patterns, identify failures, establish benchmarks,
develop guidelines and assess utilization issues20.
 Consensus building needs to take place in the surgical and
scientiﬁc community to clearly deﬁne the primary modes of
device failure. This would allow the FDA to establish more
meaningful guidance to device manufacturers than might
currently exist and create a framework for continual evaluation
of the current consensus as new information becomes available.
For HA-based viscosupplements, a signiﬁcant number of clinical
trials have been conducted on multiple injection viscosupplements
used in the knee. These trial results have varied dramatically, as have
the trial designs. It is important to collect improved randomized,
controlled, double-blind patient-reported outcomes on these
products to establish a class effect. A constant comparator such as
a saline injection should be incorporated into the clinical trials.
Viscosupplement development should be focused on reducing
the number of injections required for treatment, increasing intra-
articular residence time through cross-linking, and providing
effective treatments of other synovial joints beyond the knee such
as the hip, shoulder, ankle, temporomandibular joint, carpometa-
carpal joint, and the facet joints of the spine.
Potential research topics might include:
 Deﬁnition of a responder on a patient-reported outcome for
a viscosupplement treatment from 3 to 6 months, stating
limitation of current OARSI-OMERACT responder rate criteria. Consideration on whether or not repeated measures or
a landmark analysis is more appropriate for 3 and 6 months
viscosupplement trials.
 Deﬁnition of an appropriate placebo comparator (e.g., saline
control, sham injection, or phosphate balance solution (PBS)
control with lidocaine).
 Increased understanding of appropriate injection volumes for
different joints and appropriate endpoints measures for
different joints.
 Increased understanding of the importance of residence time
for viscosupplements and mechanism of action of synovial
ﬂuid replacement with HA-based viscosupplement material.Conclusions
It is hoped that the work undertaken by the members of the
OARSI devices working group will be helpful in enhancing the FDA
process of assessing newdevices. An ordered sequential approach to
the introduction of any “device” is critical. Additionally, a National
Registry is important but should have well-deﬁned research
objectives, a valid protocol design, clear inclusion and exclusion
criteria, a comprehensive collection of variables necessary to answer
the registry objectives, mechanisms implemented to track patients
and to insure a high level of data integrity, and ﬁnally a blinding of
data collection personnel and a method to rectify methodological
problems. Finally, appropriate dissemination and data sharing
procedures must be put in place to beneﬁt the consumers, which
includes patients, surgeons, and device manufacturers. The feed-
back process should result in an enhanced quality of care and cost-
and comparative-effectiveness of any new treatment.
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